Company / Cost of Revenue
Edwards Lifesciences Cost of Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$1.3B
FY2025
5-year range
$723.7M / $1.3B
FY2021-FY2025
Trend
+19.4%
vs FY2024
Sector context
#41 of 113
Health Care
What the data says
At $1.3B, Edwards Lifesciences's cost of revenue ranks #73 of 113 in the Health Care sector. Cost of Revenue has fluctuated over the past 10 years, ranging from $724M in FY2022 to $1.3B in FY2025.
Based on SEC 10-K filings.
$1.3B in FY2025 with a 5-year CAGR of +4.3%.
Increased from $1.2B to $1.3B over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +22.6%
- 5-Year CAGR
- +4.3%
- 10-Year CAGR
- -
Sector benchmark
#73 of 113 in Health CareTop 64% of 113This company $1.3B Sector average $11.3B
▼
-88.2% below sector average
Key checks
Key Insights
- 5-year CAGR of +4.3%, indicating consistent growth.
- In FY2025, cost of revenue increased 19.4% year-over-year.
- Ranks #41 out of 113 companies in the Health Care sector.
- Lowest cost of revenue in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score 3.16 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.3B | +19.4% |
| FY2024 | $1.1B | -10.5% |
| FY2023 | $1.2B | +72.6% |
| FY2022 | $723.7M | -42.1% |
| FY2021 | $1.2B | +15.6% |
| FY2020 | $1.1B | -3.0% |
| FY2019 | $1.1B | +18.6% |
| FY2018 | $939.4M | +7.3% |
| FY2017 | $875.3M | +9.8% |
| FY2016 | $797.4M | +29.2% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026